Adrenocortical Carcinoma

Endocrine Tumor Board of Gustave Roussy

doi:10.1016/j.ecl.2015.03.001

Adrenocortical Carcinoma

Endocrine Tumor Board of Gustave Roussy

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

53 Citations (Scopus)

Résumé

Recent developments in the treatment of adrenocortical carcinoma (ACC) include diagnostic and prognostic risk stratification algorithms, increasing evidence of the impact of historical therapies on overall survival, and emerging targets from integrated epigenomic and genomic analyses. Advances include proper clinical and molecular characterization of all patients with ACC, standardization of proliferative index analyses, referral of these patients to large cancer referral centers at the time of first surgery, and development of new trials in patients with well-characterized ACC. Networking and progress in the molecular characterization of ACC constitute the basis for significant future therapeutic breakthroughs.

langue originale	Anglais
Pages (de - à)	411-434
Nombre de pages	24
journal	Endocrinology and Metabolism Clinics of North America
Volume	44
Numéro de publication	2
Les DOIs	https://doi.org/10.1016/j.ecl.2015.03.001
état	Publié - 1 juin 2015
Modification externe	Oui

Accès au document

10.1016/j.ecl.2015.03.001

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{b3baec7af448416b8ee7b8cecbe0b6d5,

title = "Adrenocortical Carcinoma",

abstract = "Recent developments in the treatment of adrenocortical carcinoma (ACC) include diagnostic and prognostic risk stratification algorithms, increasing evidence of the impact of historical therapies on overall survival, and emerging targets from integrated epigenomic and genomic analyses. Advances include proper clinical and molecular characterization of all patients with ACC, standardization of proliferative index analyses, referral of these patients to large cancer referral centers at the time of first surgery, and development of new trials in patients with well-characterized ACC. Networking and progress in the molecular characterization of ACC constitute the basis for significant future therapeutic breakthroughs.",

keywords = "Adrenocortical carcinoma, Chemotherapy, Metastasis, Mitotane, Predictors, Prognosis, Surrogate, Survival",

author = "{Endocrine Tumor Board of Gustave Roussy} and Eric Baudin and Segolene Hescot and Amandine Berdelou and Isabelle Borget and Caroline Caramella and Frederic Dumont and Desir{\'e}e Deandreis and Frederic Deschamps and Eric Deutsch and {Al Ghuzlan}, Abir and Marc Lombes and Rossella Libe and Angelo Paci and Scoazec, {Jean Yves} and Jacques Young and Sophie Leboulleux and Martin Schlumberger",

note = "Publisher Copyright: {\textcopyright} 2015.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.ecl.2015.03.001",

language = "English",

volume = "44",

pages = "411--434",

journal = "Endocrinology and Metabolism Clinics of North America",

issn = "0889-8529",

number = "2",

}

TY - JOUR

T1 - Adrenocortical Carcinoma

AU - Endocrine Tumor Board of Gustave Roussy

AU - Baudin, Eric

AU - Hescot, Segolene

AU - Berdelou, Amandine

AU - Borget, Isabelle

AU - Caramella, Caroline

AU - Dumont, Frederic

AU - Deandreis, Desirée

AU - Deschamps, Frederic

AU - Deutsch, Eric

AU - Al Ghuzlan, Abir

AU - Lombes, Marc

AU - Libe, Rossella

AU - Paci, Angelo

AU - Scoazec, Jean Yves

AU - Young, Jacques

AU - Leboulleux, Sophie

AU - Schlumberger, Martin

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Recent developments in the treatment of adrenocortical carcinoma (ACC) include diagnostic and prognostic risk stratification algorithms, increasing evidence of the impact of historical therapies on overall survival, and emerging targets from integrated epigenomic and genomic analyses. Advances include proper clinical and molecular characterization of all patients with ACC, standardization of proliferative index analyses, referral of these patients to large cancer referral centers at the time of first surgery, and development of new trials in patients with well-characterized ACC. Networking and progress in the molecular characterization of ACC constitute the basis for significant future therapeutic breakthroughs.

AB - Recent developments in the treatment of adrenocortical carcinoma (ACC) include diagnostic and prognostic risk stratification algorithms, increasing evidence of the impact of historical therapies on overall survival, and emerging targets from integrated epigenomic and genomic analyses. Advances include proper clinical and molecular characterization of all patients with ACC, standardization of proliferative index analyses, referral of these patients to large cancer referral centers at the time of first surgery, and development of new trials in patients with well-characterized ACC. Networking and progress in the molecular characterization of ACC constitute the basis for significant future therapeutic breakthroughs.

KW - Adrenocortical carcinoma

KW - Chemotherapy

KW - Metastasis

KW - Mitotane

KW - Predictors

KW - Prognosis

KW - Surrogate

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84930320021&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2015.03.001

DO - 10.1016/j.ecl.2015.03.001

M3 - Review article

C2 - 26038209

AN - SCOPUS:84930320021

SN - 0889-8529

VL - 44

SP - 411

EP - 434

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

IS - 2

ER -